References
- Mori S, Ueki Y. Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab. Mod Rheumatol. 2011;21:628–36.
- Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40: 1256–65.
- Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.
- Miyata S, Ohkubo Y, Mutoh S. A review of the action of ta-crolimus (FK506) on experimental models of rheumatoid arthri-tis. Inflamm Res. 2005;54: 1–9.
- Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007;19:238–45.
- Lee YH, Woo JH, Choi SJ, Ji JD, Bae SC, Song GG. Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Scand J Rheumatol. 2010;39:271–8.
- Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. 2003;48:2763–8.
- Fleischmann R, Iqbal I, Stem RL. Tacrolimus in rheumatoid arthritis. Expert Opin Pharmacother. 2006;7:91–8.
- Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, Miyasaka N. Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial. Mod Rheumatol. 2011;21:458–68.
- Morita Y, Sasae Y, Sakuta T, Satoh M, Sasaki T, Kashihara N. Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol. 2008;18:379–84.
- Ogasawara M, Tamura N, Kageyama M, Onuma S, Kusaoi M, Toyama S, et al. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combina-tion therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis. Clin Rheumatol. 2012;31:251–7.
- Naniwa T, Watanabe M, Banno S, Maeda T. Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Rheumatol Int. 2009;29:1287–91.
- Mori S. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. Mod Rheumatol. 2007;17:83–91.
- Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lym-phocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008;67:380–8.
- Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, et al. Tacrolimus, a calcineurin inhibitor, over-comes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol. 2010;37:512–20.
- Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Ha-nami K, et al. Efficacy and tolerability of tocilizumab in rheu-matoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21:122–33.
- Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology (Oxford). 2011;50:1908–15.